Biologic therapy in HS shows dual benefits: improved skin lesions and potential systemic anti-inflammatory effects, as indicated by lipid profile changes. Early treatment initiation is crucial for ...

Tocilizumab is effective and safe for rheumatoid arthritis, with long-term studies supporting its use and comparable cardiovascular risk to tumor necrosis factor inhibitors. Real-world data indicate ...

Amtagvi shows a 48.8% ORR in advanced melanoma, with higher efficacy in less heavily treated patients. FDA granted accelerated approval for Amtagvi in 2024 for unresectable or metastatic melanoma ...

Tirzepatide produced significant weight loss, reduced insulin requirements, and improved glucose control without increasing hypoglycemia when used off-label in adults with type 1 diabetes (T1D), new ...

In this episode we are joined by Eric Fontana, VP of Client Solutions at Optum Life Sciences; Bethany Kalich, U.S. Medical Director, Cardiovascular at Amgen; and Christen Buseman, Director, IDN ...

Regeneron presents real-world data on EYLEA HD's effectiveness and economic benefits in treating retinal diseases at ARVO 2025. Regeneron Pharmaceuticals announced the upcoming presentation of data on ...

Patients with early Alzheimer’s disease (AD) who initiated lecanemab treatment at a specialty memory clinic showed an expected and manageable side-effect profile, new research showed. “The findings ...

In the late 1800s, the U.S. railroad system didn’t just revolutionize transportation—it catalyzed entirely new industries. Refrigerated railcars enabled a national meatpacking economy. Standard time ...